CD73: A Novel Target for Cancer Immunotherapy
Open Access
- 14 August 2010
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (16), 6407-6411
- https://doi.org/10.1158/0008-5472.can-10-1544
Abstract
The promise of cancer immunotherapy has not been translated into clinical successes, in large part because of tumor-associated immune suppression that blocks effective antitumor immunity. Recent findings show a tumor-induced immunosuppressive mechanism, whereby tumor-derived CD73 functions as an ecto-enzyme to produce extracellular adenosine, which promotes tumor growth by limiting antitumor T-cell immunity via adenosine receptor signaling. Results with small molecule inhibitors, or monoclonal antibodies targeting CD73 in murine tumor models, suggest that targeted CD73 therapy is an important alternative and realistic approach to effective control of tumor growth. In particular, it helps T-cell–based therapy by enhancing the adaptive immune response machinery, which may increase the function of tumor-infiltrating T lymphocytes, and subsequently lead to improved survival in cancer patients. Cancer Res; 70(16); 6407–11. ©2010 AACR.Keywords
This publication has 24 references indexed in Scilit:
- TH17 cells in tumour immunity and immunotherapyNature Reviews Immunology, 2010
- CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune SuppressionCancer Research, 2010
- Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer ImmunityCancer Research, 2010
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisProceedings of the National Academy of Sciences of the United States of America, 2010
- Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environmentsBlood, 2009
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionThe Journal of Experimental Medicine, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Physiological roles for ecto-5’-nucleotidase (CD73)Purinergic Signalling, 2006
- Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damageNature, 2001